https://doi.org/10.4081/reumatismo.2014.799

Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?

Vol. 66 No. 4 (2014)
Submitted: 12 October 2014
Accepted: 22 December 2014
Published: 31 March 2015
Golimumab, Biologics anti-TNF, Psoriatic arthritis, Ankylosing spondylitis, Rheumatoid arthritis.
Abstract Views: 2232
PDF: 2101
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

M. Rossini
maurizio.rossini@univr.it
Rheumatology Unit, University of Verona, Italy.
O Viapiana
Rheumatology Unit, University of Verona, Italy.
G. Orsolini
Rheumatology Unit, University of Verona, Italy.
E. Fracassi
Rheumatology Unit, University of Verona, Italy.
L. Idolazzi
Rheumatology Unit, University of Verona, Italy.
D. Gatti
Rheumatology Unit, University of Verona, Italy.
S. Adami
Rheumatology Unit, University of Verona, Italy.
M. Govoni
Rheumatology Unit, University of Ferrara, Italy.
Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite

Rossini, M., Viapiana, O., Orsolini, G., Fracassi, E., Idolazzi, L., Gatti, D., Adami, S., & Govoni, M. (2015). Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?. Reumatismo, 66(4), 285–303. https://doi.org/10.4081/reumatismo.2014.799

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.